Sex-Specific Differences in Disease-Free, Progression-Free and Overall Survival Following Enfortumab Vedotin Therapy for Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Laila Schneidewind, Jennifer Kranz, Friedemann Zengerling et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated sex-specific survival outcomes in patients with advanced or metastatic urothelial cancer treated with enfortumab vedotin. The analysis included 17 studies, revealing that while no significant difference in overall survival was found (HR 0.88), female patients had significantly better progression-free survival (HR 0.67; P < .001).
Key findings
- No significant difference in overall survival between sexes (HR 0.88; P = .17).
- Female patients had significantly better progression-free survival (HR 0.67; P < .001).
- Adjustment analyses indicated a stronger female advantage in progression-free survival (HR 0.41; P < .001).
- Limited data were available for disease-free, cancer-specific, and event-free survival.
Why it matters
Understanding sex-specific differences in survival outcomes can inform treatment decisions and highlight the need for tailored approaches in managing advanced urothelial cancer, particularly regarding the efficacy of enfortumab vedotin.
What to keep in mind
The risk of bias was assessed as moderate, and there was significant publication bias affecting the results.